Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIN-117 in Major Depressive Disorder
NCT03446846Phase 2
Key facts
- Status
- Completed
- Start
- Mar 2018
- Primary completion
- Nov 2019
- Countries
- 7
- Sponsor
- Minerva Neurosciences, Inc.
- Modality
- Multivalent & Scaffold-Based Small Molecules, Classical Binding Small Molecules
- Drugs
- min-117
- Conditions
- major depressive disorder (MDD)
01
Overview
Phase 2, randomised, double-blind trial of min-117 in major depressive disorder (MDD) (3 arms), sponsored by Minerva Neurosciences, Inc. Primary endpoint: Montgomery-Asberg Depression Rating Scale Total Score at 6 weeks. Started Mar 2018; status: completed.
02
Design
3 arms- Study design
- RandomizedDouble-blind
5.0 mg MIN-117
MIN-117 5.0 mg orally daily
2.5 mg MIN-117
MIN-117 2.5 mg orally daily
Placebo
Placebo orally daily
03
Who it enrols
Adults 18-65 with moderate to severe MDD with anxious distress, history of at least one previous episode, and inadequate response to prior antidepressant treatment.
04
Endpoints
Primary
Montgomery-Asberg Depression Rating Scale Total Score
Secondary
Hamilton Anxiety Scale
Clinical Global Impression of Severity Scale
Clinical Global Impression of Improvement Scale
Beyond the preview
Go deeper on NCT03446846.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03446846.